FDA clears Nurix Therapeutics, Inc.'s GS-6791 for inflammatory disorders; Nurix earns $5M milestone from Gilead. Click for my ...

Nurix is eligible for an additional $420 million in development, regulatory and commercial milestones associated with the ...

Collaboration partner, Gilead Sciences, to begin Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) study in healthy volunteers in Q2 2025 GS-6791/NX-0479 has potential clinical app ...

Horizons Across Disease, Demography and Technology," in Washington, D.C., bringing together industry, academic, and non-profit leaders from around the world to ...

Nektar Therapeutics’s NKTR share price has surged by 6.81%, which has investors questioning if this is right time to sell.

Fixstars Corporation (TSE Prime: 3687, US Headquarters: Irvine, USA), a company dedicated to advancing AI technologies through world-class performance engineering, today announced its participation as ...

A desi dengue vaccine is undergoing the third phase of clinical trials in India, a top Indian Council of Medical Research ...

The latest start-up to emerge from the Roivant stable is named Priovant Therapeutics, and has been formed to develop a JAK1/TYK2 inhibitor originated by Pfizer as a treatment for autoimmune diseases.

Sanofi is continuing to splash the cash for autoimmune and immunology assets this spring by penning a new deal with ...

Partnership bolsters Boehringer’s autoimmune and inflammatory disease pipeline portfolio aiming to tackle areas of high unmet patient need. The ...

The startup, affiliated with China-based antibody designer Helixon Therapeutics, is developing bispecific drugs aimed at ...